Technical Analysis for TOCA - Tocagen Inc.

Grade Last Price % Change Price Change
grade F 0.56 1.36% 0.01
TOCA closed up 1.36 percent on Tuesday, October 15, 2019, on 21 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical TOCA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.36%
Narrow Range Bar Range Contraction 1.36%
NR7 Range Contraction 1.36%
Wide Bands Range Expansion 1.36%
Oversold Stochastic Weakness 1.36%
Narrow Range Bar Range Contraction -1.48%
New 52 Week Low Weakness -1.48%

Older signals for TOCA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.
Biotechnology Cancer Life Sciences Biology Gene Therapy Applied Genetics
Is TOCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.75
52 Week Low 0.53
Average Volume 931,762
200-Day Moving Average 7.0027
50-Day Moving Average 2.4689
20-Day Moving Average 0.6668
10-Day Moving Average 0.605
Average True Range 0.1747
ADX 43.46
+DI 15.4264
-DI 40.637
Chandelier Exit (Long, 3 ATRs ) 0.5659
Chandelier Exit (Short, 3 ATRs ) 1.0541
Upper Bollinger Band 0.8411
Lower Bollinger Band 0.4925
Percent B (%b) 0.19
BandWidth 52.279544
MACD Line -0.5252
MACD Signal Line -0.6479
MACD Histogram 0.1227
Fundamentals Value
Market Cap 11.09 Million
Num Shares 19.8 Million
EPS -6.18
Price-to-Earnings (P/E) Ratio -0.09
Price-to-Sales 4252.02
Price-to-Book 2.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.63
Resistance 3 (R3) 0.64 0.61 0.62
Resistance 2 (R2) 0.61 0.59 0.61 0.62
Resistance 1 (R1) 0.59 0.58 0.58 0.58 0.61
Pivot Point 0.56 0.56 0.56 0.56 0.56
Support 1 (S1) 0.54 0.54 0.53 0.54 0.51
Support 2 (S2) 0.51 0.53 0.51 0.50
Support 3 (S3) 0.49 0.51 0.50
Support 4 (S4) 0.49